Glycoproteins, glycoconjugates of proteins generated by glycosylation, are involved in nearly all biological processes, and also have become the fastest growing fields in the pharmaceutical industry. —
Equipped with top-class scientific experts and technologies as well as substantial experience in the field of therapeutic glycoprotein development, Creative Biolabs has updated its glyco-based vaccine development, covering glycoprotein-based vaccine development, glycopeptide-based cancer vaccine development and carbohydrate-based vaccine development.
· Glycoprotein-based Vaccine Development
There are examples of glycoprotein-based vaccine development such as for hepatitis C virus (HCV), cytomegalovirus (CMV) and respiratory syncytial virus (RSV). At Creative Biolabs, various leading technologies are available for glycoprotein vaccine candidate development.
Firstly, Glycoprotein by glyco-engineered platforms are used to modify, manipulate and incorporate in a site-specific way glycosidic residue on proteins with the established glyco-engineered mammalian cell expression system, glyco-engineered pichia pastoris expression system and glyco-engineered plant-based expression system. Creative Biolabs also provides site-specific glycosylation of proteins by chemical or (chemo) enzymatic strategies, allowing for the synthesis of defined glycoproteins with a precisely controlled epitope. Then, Custom glycoprotein synthesis is well-performed through glycoprotein remodeling, native chemical ligation (NCL), expressed protein ligation (EPL), Staudinger ligation or sugar-assisted ligation.
· Glycopeptide-based Cancer Vaccine Development
Creative Biolabs has engineered a synthetic non-natural T-helper epitope, which can bind to a wide range of HLA class II molecules. Linear peptides linked to this carrier protein are found to be potent immunogens in vivo. Both two carrier proteins above can be used in the development of cancer vaccine candidates.
Creative Biolabs has accumulated extensive experience in offering high-quality synthesis of diverse TACA glycopeptide B-cell epitopes, including Tn, T, sialyl-Tn, sialyl-T antigens, Lewis series antigens, and glycolipid-derived antigens, covalently linked to a carrier protein or peptide to induce T-helper epitope cell response.
· Carbohydrate-based Vaccine Development
Naturally derived glycans like cell-surface polysaccharides from bacteria, viruses, and parasites have served as valuable antigenic targets for vaccine development. Besides naturally derived glycans, Creative Biolabs has developed cutting-edge platforms for Custom Glycan Synthesis, using chemical and chemoenzymatic methods.
The experienced scientists are proficient in employing diverse strategies for the conjugation of carbohydrate antigens to carrier proteins or peptides to further improve the safety and efficacy of glycovaccines. The strategies include non-specific methods and site-specific methods, including cyanylation, carbodimide mediated condensation, thioalkylation, active ester, etc.
Rational designed, structurally defined, and first-in-class technologies offer a promising alternative for developing future glyco-based vaccines. As a leading specialist in in glycoscience, Creative Biolabs is always committed to providing high-quality glycoprotein services to promote the progress of related projects. For more detailed information, please visit the official website on https://www.creative-biolabs.com/glycoprotein/.
About Creative Biolabs
Established in 2004, Creative Biolabs is a leading customer service provider in the field of therapeutic glycoprotein development. Equipped with the world-leading technology platforms and professional scientific staff, Creative Biolabs is dedicated to providing high-quality glycoprotein production and corresponding analysis service.
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Release ID: 88963789